Lansoprazole Injection for Gastric Ulcer/Duodenal Ulcer
Model No.: lan-1
Lansoprazole injection for gastric ulcer/duodenal ulcer
Lansoprazole is a proton-pump inhibitor (PPI) which inhibits the stomach's production of gastric acids. It is manufactured by a number of companies worldwide under several brand names. In the United States, it was first approved by the Food and Drug Administration (FDA) in 1995. Prevacid patent protection expired on November 10, 2009.Since 2009, lansoprazole has been available over the counter (OTC) in the U.S. in a 15-mg dose marketed by Novartis as Prevacid 24HR.
Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available. It is a racemic 1:1 mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and levolansoprazole. Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the enantiomeric shift.
Lansoprazole's plasma elimination half-life (1.5 h) is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression). and the effects of the drug last for over 24 hours after it has been used for a day or more. Lansoprazole, 30-mg administered nasogastrically, effectively controls intragastric pH and is an alternative to intravenous pantoprazole in patients who are unable to swallow solid-dose formulations.
Lansoprazole is indicated for treatment of:
Ulcers of the stomach and duodenum, and NSAID-induced ulcers
Helicobacter pylori infection, alongside antibiotics (adjunctive treatment), treatment to kill H. pylori causing ulcers or other problems involves using two other drugs besides lansoprazole known as "triple therapy", and involves taking twice daily for 10 or 14 days lansoprazole 30-mg
Gastroesophageal reflux disease
Lansoprazole interacts with several other drugs, either due to its own nature or as a PPI.
Increases plasma concentrations of cilostazol (risk of toxicity)
Lansoprazole possibly interacts with, amongst other drugs:
aminophylline and theophylline
Side effects of PPIs in general and lansoprazole in particular may include:
Common: diarrhea, abdominal pain
Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions including (erythroderma Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
PPIs may be associated with a greater risk of hip fractures and Clostridium difficile-associated diarrhea
The lansoprazole molecule is off-patent and so generic drugs are available under many brand names in many countries; there are patents covering some formulations in effect as of 2015. Contact us if you need more details on Lansoprazole. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Gastric Ulcer、Duodenal Ulcer. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : Gastro-Intestinals Drug